BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 210 filers reported holding BRIDGEBIO PHARMA INC in Q4 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,635 | +59.0% | 61,976 | +3.7% | 0.00% | – |
| Q2 2023 | $1,028 | +12.2% | 59,756 | +8.3% | 0.00% | – |
| Q1 2023 | $916 | +80.7% | 55,201 | -17.0% | 0.00% | – |
| Q4 2022 | $507 | -99.9% | 66,522 | -20.1% | 0.00% | – |
| Q3 2022 | $828,000 | +1.1% | 83,286 | -7.7% | 0.00% | – |
| Q2 2022 | $819,000 | +21.9% | 90,197 | +36.2% | 0.00% | – |
| Q1 2022 | $672,000 | -4.0% | 66,224 | +57.7% | 0.00% | – |
| Q4 2021 | $700,000 | -66.4% | 41,986 | -5.6% | 0.00% | – |
| Q3 2021 | $2,085,000 | -93.7% | 44,493 | -91.8% | 0.00% | -100.0% |
| Q2 2021 | $33,111,000 | -11.3% | 543,165 | -10.4% | 0.00% | -25.0% |
| Q1 2021 | $37,329,000 | +1637.0% | 605,990 | +1905.7% | 0.00% | – |
| Q4 2020 | $2,149,000 | +111.5% | 30,214 | +11.6% | 0.00% | – |
| Q3 2020 | $1,016,000 | +73.4% | 27,073 | +50.8% | 0.00% | – |
| Q2 2020 | $586,000 | +14.0% | 17,955 | +1.4% | 0.00% | – |
| Q1 2020 | $514,000 | – | 17,711 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |